HRP20240116T1 - Antigeni peptidi, namijenjeni sprječavanju i liječenju zloćudnih tumora b-stanica - Google Patents
Antigeni peptidi, namijenjeni sprječavanju i liječenju zloćudnih tumora b-stanica Download PDFInfo
- Publication number
- HRP20240116T1 HRP20240116T1 HRP20240116TT HRP20240116T HRP20240116T1 HR P20240116 T1 HRP20240116 T1 HR P20240116T1 HR P20240116T T HRP20240116T T HR P20240116TT HR P20240116 T HRP20240116 T HR P20240116T HR P20240116 T1 HRP20240116 T1 HR P20240116T1
- Authority
- HR
- Croatia
- Prior art keywords
- antigenic peptide
- accordance
- seq
- pharmaceutical preparation
- cell
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 28
- 230000000890 antigenic effect Effects 0.000 title claims 25
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 3
- 206010028980 Neoplasm Diseases 0.000 title claims 2
- 201000011510 cancer Diseases 0.000 title claims 2
- 230000002265 prevention Effects 0.000 title claims 2
- 230000036210 malignancy Effects 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 4
- 239000002105 nanoparticle Substances 0.000 claims 3
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 2
- 208000011778 T-cell/histiocyte rich large B cell lymphoma Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 2
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001124—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Claims (18)
1. Antigeni peptid, naznačen time što se sastoji od aminokiselinskog slijeda kao što je iznijet u SEQ ID NO: 65.
2. Nanočestica, naznačena time što sadrži antigeni peptid u skladu s patentnim zahtjevom 1.
3. Stanica, naznačena time što sadrži antigeni peptid u skladu s patentnim zahtjevom 1.
4. Nukleinska kiselina, naznačena time što kodira antigeni peptid u skladu s patentnim zahtjevom 1.
5. Stanica domaćin, naznačena time što sadrži nukleinska kiselina u skladu s patentnim zahtjevom 4.
6. Citotoksični limfocit T (CTL), naznačen time što je specifičan za antigeni peptid u skladu s patentnim zahtjevom 1.
7. Farmaceutski pripravak, naznačen time što sadrži
– antigeni peptid u skladu s patentnim zahtjevom 1,
– nanočesticu u skladu s patentnim zahtjevom 2, ili
– stanicu u skladu s patentnim zahtjevom 3.
8. Farmaceutski pripravak u skladu s patentnim zahtjevom 7, naznačen time što pripravak sadrži antigeni peptid u skladu s patentnim zahtjevom 1 i najmanje jedan različiti antigeni peptid, koji se sastoji od aminokiselinskog slijeda kao što je iznijet u bilo kojem od SEQ ID NO 1-64, 66-257 i 476-500.
9. Farmaceutski pripravak u skladu s patentnim zahtjevom 8, naznačen time što sadrži tri ili četiri različita antigena peptida, uključujući antigeni peptid u skladu s patentnim zahtjevom 1 i dva ili tri različita antigena peptida, koje se bira iz skupine koju čine:
– antigeni peptid koji se sastoji od aminokiselinskog slijeda kao što je iznijet u SEQ ID NO: 110;
– antigeni peptid koji se sastoji od aminokiselinskog slijeda kao što je iznijet u SEQ ID NO: 114; i
– antigeni peptid koji se sastoji od aminokiselinskog slijeda kao što je iznijet u SEQ ID NO: 220.
10. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 7-9, naznačen time što dodatno sadrži pomoćni peptid.
11. Farmaceutski pripravak u skladu s patentnim zahtjevom 10, naznačen time što se pomoćni peptid sastoji od aminokiselinskog slijeda u skladu s SEQ ID NO: 475.
12. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 7 do 11, naznačen time što pripravak sadrži:
– antigeni peptid u skladu s patentnim zahtjevom 1;
– antigeni peptid koji se sastoji od SEQ ID NO: 110;
– antigeni peptid koji se sastoji od SEQ ID NO: 114;
– antigeni peptid koji se sastoji od SEQ ID NO: 220; i
– peptid koji se sastoji od aminokiselinskog slijeda u skladu s SEQ ID NO: 475.
13. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 7 do 12, naznačen time što dodatno sadrži adjuvans, gdje je adjuvans Montanide.
14. Kombinacija, naznačena time što je kombinacija antigenog peptida u skladu s patentnim zahtjevom 1 s antigenim peptidom koji se sastoji od aminokiselinskog slijeda kao što je iznijet u bilo kojem od SEQ ID NO 1-64, 66-257 i 476-500.
15. Antigeni peptid, u skladu s patentnim zahtjevom 1,
nanočestica u skladu s patentnim zahtjevom 2,
stanica u skladu s patentnim zahtjevom 3,
farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 7 do 13, ili
kombinacija u skladu s patentnim zahtjevom 14
naznačeni time što su namijenjeni upotrebi u medicini.
16. Antigeni peptid, farmaceutski pripravak ili kombinacija, naznačeni time što su namijenjeni upotrebi u skladu s patentnim zahtjevom 15 u sprječavanju i/ili liječenju zloćudnog tumora B-stanica.
17. Antigeni peptid, farmaceutski pripravak ili kombinacija namijenjeni upotrebi u skladu s patentnim zahtjevom 16, naznačeni time što je zloćudni tumor B-stanica limfom B-stanica, kojeg se bira iz skupine koju čine nehodgkinovski limfom (NHL), difuzni limfom velikih B-stanica (DLBCL), NOS (de novo i transformiran iz indolentnih), primarni medijastinalni limfom velikih B-stanica (PMBCL), limfom velikih B-stanica bogat T-stanicama/histiocitima (TCHRBCL), Burkittov limfom, limfom stanica plašta (MCL), limfom rubne zone (MZL), te folikularni limfom (FL).
18. Multimer peptid-MHC (pMHC), naznačen time što sadrži antigeni peptid u skladu s patentnim zahtjevom 1.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19306475 | 2019-11-15 | ||
| EP2020079257 | 2020-10-16 | ||
| PCT/EP2020/082101 WO2021094562A2 (en) | 2019-11-15 | 2020-11-13 | Antigenic peptides for prevention and treatment of b-cell malignancy |
| EP20804279.6A EP4021487B1 (en) | 2019-11-15 | 2020-11-13 | Antigenic peptides for prevention and treatment of b-cell malignancy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240116T1 true HRP20240116T1 (hr) | 2024-04-12 |
Family
ID=75911928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240116TT HRP20240116T1 (hr) | 2019-11-15 | 2020-11-13 | Antigeni peptidi, namijenjeni sprječavanju i liječenju zloćudnih tumora b-stanica |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11759508B2 (hr) |
| EP (2) | EP4357356A2 (hr) |
| JP (1) | JP2023501204A (hr) |
| CN (1) | CN114746112A (hr) |
| AU (1) | AU2020384926A1 (hr) |
| BR (1) | BR112022009100A2 (hr) |
| CA (1) | CA3153470A1 (hr) |
| DK (1) | DK4021487T3 (hr) |
| ES (1) | ES2971929T3 (hr) |
| FI (1) | FI4021487T3 (hr) |
| HR (1) | HRP20240116T1 (hr) |
| HU (1) | HUE065075T2 (hr) |
| LT (1) | LT4021487T (hr) |
| MX (1) | MX2022005704A (hr) |
| PL (1) | PL4021487T3 (hr) |
| RS (1) | RS65262B1 (hr) |
| SI (1) | SI4021487T1 (hr) |
| WO (1) | WO2021094562A2 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11478537B2 (en) | 2016-10-07 | 2022-10-25 | Enterome S.A. | Immunogenic compounds for cancer therapy |
| EP3522917A2 (en) | 2016-10-07 | 2019-08-14 | Enterome S.A. | Microbiota sequence variants of tumor-related antigenic epitopes |
| US11478538B2 (en) | 2016-10-07 | 2022-10-25 | Enterome S.A. | Immunogenic compounds for cancer therapy |
| HRP20230007T1 (hr) | 2018-04-11 | 2023-03-03 | Enterome S.A. | Antigenski peptidi, namijenjeni sprječavanju i liječenju raka |
| WO2023167213A1 (ja) * | 2022-03-01 | 2023-09-07 | ｂｉｔＢｉｏｍｅ株式会社 | アミノ酸残基配列を同定するための方法，プログラム及び記録媒体 |
| WO2024025397A1 (ko) * | 2022-07-29 | 2024-02-01 | 주식회사 엘지화학 | 항원 전달용 재조합 융합 단백질 및 이의 이용 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
| CA2006700A1 (en) | 1989-01-17 | 1990-07-17 | Antonello Pessi | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| US5635363A (en) | 1995-02-28 | 1997-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for the detection, quantitation and purification of antigen-specific T cells |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| EP1880735A3 (en) | 1999-03-19 | 2008-03-12 | GlaxoSmithKline Biologicals S.A. | Vaccine |
| JP2002541808A (ja) | 1999-04-09 | 2002-12-10 | テクラブ， インコーポレイテッド | ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア |
| FR2798128B1 (fr) | 1999-09-06 | 2001-11-16 | Inst Nat Sante Rech Med | Moyens de detection et de purification de populations lymphocytaires t cd8+ specifiques de peptides presentes dans le contexte hla |
| US7812116B2 (en) * | 2003-07-03 | 2010-10-12 | Rush University Medical Center | Immunogenic peptides |
| PL2119726T5 (pl) | 2008-05-14 | 2018-04-30 | Immatics Biotechnologies Gmbh | Nowe i silne peptydy MHC klasy II pochodzące z surwiwiny i neurokanu |
| WO2013040142A2 (en) * | 2011-09-16 | 2013-03-21 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| RS62993B1 (sr) | 2011-10-03 | 2022-03-31 | Modernatx Inc | Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe |
| US20140371302A1 (en) | 2011-12-29 | 2014-12-18 | Modema Therapeutics, Inc. | Modified mrnas encoding cell-penetrating polypeptides |
| EP2639299A1 (en) | 2012-03-16 | 2013-09-18 | Invectys | Universal cancer peptides derived from telomerase |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| AU2017254477A1 (en) * | 2016-04-18 | 2018-11-01 | Jennifer G. ABELIN | Improved HLA epitope prediction |
| CN106008695A (zh) * | 2016-06-19 | 2016-10-12 | 苏州普罗达生物科技有限公司 | 一种关于cd19免疫原多肽及其用途 |
| US20190201443A1 (en) * | 2017-09-06 | 2019-07-04 | California Institute Of Technology | Signaling and antigen-presenting bifunctional receptors (sabr) |
| US20200256877A1 (en) * | 2017-10-09 | 2020-08-13 | Enterome S.A. | Microbiota Sequence Variants Of Tumor-Related Antigenic Epitopes |
| HRP20230007T1 (hr) * | 2018-04-11 | 2023-03-03 | Enterome S.A. | Antigenski peptidi, namijenjeni sprječavanju i liječenju raka |
| US20210382068A1 (en) * | 2018-10-02 | 2021-12-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
-
2020
- 2020-11-13 HU HUE20804279A patent/HUE065075T2/hu unknown
- 2020-11-13 CA CA3153470A patent/CA3153470A1/en active Pending
- 2020-11-13 EP EP23220228.3A patent/EP4357356A2/en active Pending
- 2020-11-13 PL PL20804279.6T patent/PL4021487T3/pl unknown
- 2020-11-13 RS RS20240132A patent/RS65262B1/sr unknown
- 2020-11-13 LT LTEPPCT/EP2020/082101T patent/LT4021487T/lt unknown
- 2020-11-13 ES ES20804279T patent/ES2971929T3/es active Active
- 2020-11-13 AU AU2020384926A patent/AU2020384926A1/en active Pending
- 2020-11-13 BR BR112022009100A patent/BR112022009100A2/pt unknown
- 2020-11-13 JP JP2022525171A patent/JP2023501204A/ja active Pending
- 2020-11-13 DK DK20804279.6T patent/DK4021487T3/da active
- 2020-11-13 HR HRP20240116TT patent/HRP20240116T1/hr unknown
- 2020-11-13 EP EP20804279.6A patent/EP4021487B1/en active Active
- 2020-11-13 FI FIEP20804279.6T patent/FI4021487T3/fi active
- 2020-11-13 WO PCT/EP2020/082101 patent/WO2021094562A2/en active Application Filing
- 2020-11-13 SI SI202030352T patent/SI4021487T1/sl unknown
- 2020-11-13 MX MX2022005704A patent/MX2022005704A/es unknown
- 2020-11-13 CN CN202080083161.5A patent/CN114746112A/zh active Pending
-
2022
- 2022-05-02 US US17/734,694 patent/US11759508B2/en active Active
-
2023
- 2023-07-19 US US18/354,966 patent/US20240033335A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RS65262B1 (sr) | 2024-03-29 |
| WO2021094562A2 (en) | 2021-05-20 |
| EP4021487A2 (en) | 2022-07-06 |
| SI4021487T1 (sl) | 2024-03-29 |
| HUE065075T2 (hu) | 2024-04-28 |
| EP4021487B1 (en) | 2023-12-27 |
| US20220323561A1 (en) | 2022-10-13 |
| EP4357356A2 (en) | 2024-04-24 |
| BR112022009100A2 (pt) | 2022-07-26 |
| FI4021487T3 (fi) | 2024-02-06 |
| LT4021487T (lt) | 2024-02-12 |
| JP2023501204A (ja) | 2023-01-18 |
| MX2022005704A (es) | 2022-06-08 |
| US11759508B2 (en) | 2023-09-19 |
| DK4021487T3 (da) | 2024-02-12 |
| ES2971929T3 (es) | 2024-06-10 |
| PL4021487T3 (pl) | 2024-04-15 |
| CN114746112A (zh) | 2022-07-12 |
| US20240033335A1 (en) | 2024-02-01 |
| WO2021094562A3 (en) | 2021-09-30 |
| CA3153470A1 (en) | 2021-05-20 |
| AU2020384926A1 (en) | 2022-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240116T1 (hr) | Antigeni peptidi, namijenjeni sprječavanju i liječenju zloćudnih tumora b-stanica | |
| HRP20190799T1 (hr) | Imunocitokini na bazi il-15 i sushi domene il-15r alfa | |
| Ghaffari-Nazari et al. | Improving multi-epitope long peptide vaccine potency by using a strategy that enhances CD4+ T help in BALB/c mice | |
| AU2019250206A1 (en) | Novel immunogenic peptides | |
| HRP20141233T1 (hr) | PEPTIDNA CJEPIVA DOBIVENA IZ EphA4 | |
| RU2014144133A (ru) | Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин | |
| RU2009118432A (ru) | Пептидные вакцины против рака с экспрессией полипептидов mphosph1 или depdc1 | |
| HRP20211113T1 (hr) | Pripravci i metode za ciljanu dostavu citokina | |
| Håkerud et al. | Intradermal photosensitisation facilitates stimulation of MHC class-I restricted CD8 T-cell responses of co-administered antigen | |
| WO2013082535A3 (en) | Controlled-release peptide compositions and uses thereof | |
| RU2012127358A (ru) | Олигопептиды imp-3 и содержащие их вакцины | |
| CL2020003293A1 (es) | Péptido que consiste en la secuencia de aminoácidos de seq id no: 42; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969) | |
| RU2015143164A (ru) | Пептиды kntc2 и содержащие их вакцины | |
| RU2014109137A (ru) | Пептиды mphosph1 и вакцины, включающие их | |
| RU2009129531A (ru) | Вакцины на основе пептида foxp3 | |
| RU2012136464A (ru) | Модифицированные пептиды melk и содержащие их вакцины | |
| JP2013523084A5 (hr) | ||
| RU2019113989A (ru) | Лекарственное средство | |
| RU2014121502A (ru) | Пептиды торк и содержащие их вакцины | |
| Pemberton et al. | Influenza peptide-induced self-lysis and down-regulation of cloned cytotoxic T cells. | |
| HRP20240359T1 (hr) | Peptidi iz piwil1 | |
| CL2021001479A1 (es) | Péptido; uso de composiciones; composición farmacéutica; uso de un anticuerpo para terapia; uso de un anticuerpo para elisa, inmunohistoquímica y/o formación de imágenes; receptor de linfocito t; y uso de un linfocito t citotóxico activado (divisional de la solicitud n° 201701391) | |
| RU2011120447A (ru) | Эпитопные пептиды rab6kifl/kif20a и содержащие их вакцины | |
| JP2014506114A5 (hr) | ||
| RU2010126154A (ru) | Эпитопные пептиды stat3 |